Despite strong
multi-year share gains and a powerful
1-year run, it's still worth considering and investing in the
Altria Group (MO), as evidenced by KFA Private Wealth Group LLC's new $2.07 million investment. The tobacco company's market share remains a contentious issue, but still offers a significant
6.1% yield on dividends. Altria's shares have recently experienced a 2.8% decline, however, they were on the rise in February.
Barclays raised its price target for Altria from $57 to $63, suggesting strong confidence in the Group's future. Meanwhile, several companies have either sliced or boosted their holdings in Altria, reflecting mixed sentiments among investors. Altria's
dividend steadiness has been spotlighted, while new risks from e-vapor antitrust classes await. Despite mixed signals on valuation and share price momentum, UBS's reaffirmed rating steadiy supports the company. Altria recently missed estimates due to a revenue decline and margin pressure, with some investors questioning whether the Group remains a strong bet on the market. The company's
smoke-free strategy shift has drawn investor attention, and FDA approval for On! PLUS and cigarette declines have positioned the group attractively in the market. Altria's Q4 2025 earnings call highlighted strong EPS growth despite volume declines.
Altria Group MO News Analytics from Wed, 10 Sep 2025 07:00:00 GMT to Sat, 21 Mar 2026 10:34:53 GMT -
Rating 2
- Innovation 4
- Information 8
- Rumor -6
